Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04452747
Other study ID # RECHMPL19_0044
Secondary ID 7756
Status Completed
Phase N/A
First received
Last updated
Start date November 16, 2020
Est. completion date March 1, 2023

Study information

Verified date May 2023
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Labour induction is an obstetrical procedure, which artificially starts the process of cervix dilation, in order to induce labour. Several methods of labour induction exist : mechanical ones (using dilatation balloons) or pharmacological ones (using prostaglandins or oxytocin). This trial aims to compare, in case of non-favourable cervix, the strategy of labour induction using the Propess® method first (Dino-first) versus the strategy beginning with the use of a dilatation balloon (Ballon-first), with respect of the usual practice and the current guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 450
Est. completion date March 1, 2023
Est. primary completion date October 2, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women with singleton pregnancy - Fetus with cephalic presentation - Intact membranes between 37 and 42 weeks of amenorrhea - Medical indication for labour induction according to the "Haute Autorité de Santé" (HAS) guidelines - Unfavourable cervix (Bishop scoring < 7) - Age > 18 years-old - Person affiliated to a healthcare system - Good understanding of the French language Exclusion Criteria: - Previous C-section or uterine incision - Placenta previa - Metrorrhagia of unknown origin - Lethal foetal abnormality - Hyperreactivity to one of the molecules used for the induction (dinoprostone or oxytocin) or to latex - Subject participants to another biomedical research - Subject under legal guardianship or curatorship

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Vaginal Dinoprostone system (Propess®)
Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
Dilatation balloon
Labour will be induced using a cervix dilatation balloon as a first strategy

Locations

Country Name City State
France Montpellier University Hospital Montpellier
France Nimes University Hospital Nîmes

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of vaginal deliveries Rate of vaginal deliveries (both spontaneous or instrumentally assisted) On the day of the delivery
Secondary Rate of spontaneous vaginal deliveries Number of spontaneous vaginal deliveries On the day of the delivery
Secondary Rate of instrumentally assisted vaginal deliveries, including the reason for the assistance Number of instrumentally assisted vaginal deliveries, including the reason for the assistance On the day of the delivery
Secondary Rate of C-section including the reason for the C-section Number of C-section including the reason for the C-section. The reasons for the C-section can be : a failure of dilatation at the first stage of the labour (between 0 and 10 cm), an absence of foetal descent at the second stage of labour, a foetal reason or a maternal reason) On the day of the delivery
Secondary Timeframe between the beginning of the induction and the beginning of the labour Time elapsed between the beginning of the induction and the beginning of the labour On the day of the delivery
Secondary Cumulated rate of spontaneous vaginal deliveries Cumulated number of spontaneous vaginal deliveries at 12 hours, 24 hours and 48 hours at 12 hours, 24 hours and 48 hours
Secondary Rate of labour induction failure Rate of labour induction failure is measure by the number of C-sections carried out due to a latency phase (0-6cm), which lasted more than 24 hours, together with the administration of oxytocin for at least 12 to 18 hours after the membranes artifically broke. On the day of the delivery
Secondary Rate of secondary or tertiary use of Propess, Foley catheter of intra-veinous oxytocin Number of secondary or tertiary use of Propess, Foley catheter of intra-veinous oxytocin On the day of the delivery
Secondary Rate of peridural anaesthesia during labour Number of peridural anaesthesia during labour On the day of the delivery
Secondary Rate of uterine hyperstimulation without impact on the foetus Uterine hyperstimulation is described as a number of contractions of 6 or more within 10 minutes, repeating at least twice). Foetal impact is defined as a slowing of the foetal heart rate. On the day of the delivery
Secondary Rate of uterine hyperstimulation with an impact on the foetus Uterine hyperstimulation is described as a number of contractions of 6 or more within 10 minutes, repeating at least twice). Foetal impact is defined as a slowing of the foetal heart rate. On the day of the delivery
Secondary Rate of uterine hypertonia Uterine hypertonia is describes as a frequency of contractions every 2 minutes or less together with a slowing of the foetal heart rate. On the day of the delivery
Secondary Rate of post-partum haemorrhagia Rate of post-partum haemorrhagia above 500 mL, above 1000 mL, transfusion level and number of packed red blood cells transfused On the day of the delivery
Secondary Rate of uterine rupture Number of patients with a uterine rupture On the day of the delivery
Secondary Rate of intra-uterine infections Number of patients with intra-uterine infections (body temperature above 38°C measured twice within 30 minutes, associated to 2 criteria within the followings: foetal tachycardia above 160 beats per minute, pain of the uterus or painful uterus contractions ou spontaneous labour induction, or purulent amniotic fluid. On the day of the delivery
Secondary Rate of post-partum infections Number of patients with post-partum infections (body temperature above 38°C with antibiotic treatment, urinary tract infections, bacteriological endometritis) One week after day of the delivery
Secondary Rate of neonatal asphyxia Number of fetuses with neonatal asphyxia On the day of the delivery
Secondary Rate of hospitalization in Neonatal intensive care unit Number of newborn babies hospitalized in Neonatal intensive care unit Up to four days after the delivery
Secondary Rate of proven bacteriological infections in newborn babies Number of proven bacteriological infections in newborn babies Up to four days after the delivery
Secondary Rate of metrorrhagias while putting in place the dilatation balloon or the vaginal pad (dinoprostone) Number of women who experienced metrorrhagias while putting in place the dilatation balloon or the vaginal pad (dinoprostone) On the day of the delivery
Secondary Pain level linked to the inflation of the dilatation balloon and requiring the partial deflation of the balloon Measurement of Pain will be made using an Visual Analog Scale (VAS). The pain level will be linked to the inflation of the dilatation balloon and requiring the partial deflation of the balloon On the day of the delivery
Secondary Pain level recorded at different times of the labour induction Measurement will be made using a Visual Analog Scale (VAS) and will be recorded at different times of the dilatation balloon or the dinoprostone vaginal pad set up On the day of the delivery
Secondary Assessment of the patient experience of the labour induction Patient experience will be assessed using the W-DEQ (Wijma Delivery Expectancy/Experience Questionnaire) Up to two weeks after the delivery
Secondary Assessment of each strategy direct main costs The costs of the treatment and duration of the hospitalization will be measured through study completion, an average of 3 years
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A